Antibody-induced apoptosis

Details Antibody-induced apoptosis Antibody-induced apoptosis

2007-10-30

2010-10-12

Goddard, Laura B (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S138100, C424S141100, C424S142100

Reexamination Certificate

active

07811566

ABSTRACT:
Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.

REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4954617 (1990-09-01), Fanger et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5489525 (1996-02-01), Pastan
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 5910486 (1999-06-01), Curiel et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6399063 (2002-06-01), Hudziak et al.
patent: 6458356 (2002-10-01), Arakawa et al.
patent: 7354583 (2008-04-01), Arakawa et al.
patent: 5317084 (1993-12-01), None
patent: WO 94/00136 (1994-01-01), None
patent: WO 96/07321 (1996-03-01), None
patent: WO 98/17797 (1998-04-01), None
Kita et al, Biochemical and Biophysical Research Communications, 1996, 226:59-69, IDS.
In re Alonso, Oct. 2008, US Court of Appeals for the Federal Circuit (p. 1-11 + cover).
Phillips et al., “Targeting HER2-Positive Breast Cancer with Transtuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,” Cancer Res., 68(22): 9280-9290 (2008).
Yarden et al., “Growth Factor Receptor Tyrosine Kinases,” Ann. Rev. Biochem., 57: 443-478 (1988).
Summons to attend oral proceedings pursuant to Rule 115(1) EPC dated Feb. 26, 2008, for European Patent Application No. 96943576.7 (4 pages).
Response to the Summons mailed Aug. 1, 2008, for European Patent Application No. 96943576.7 (9 pages).
Interlocutory decision in Opposition proceedings (Art. 101(3)(a) and 106(2) EPC) dated Dec. 11, 2008, for European Patent Application No. 96943576.7 (47 pages).
Provision of the minutes in accordance with Rule 124(4) EPC dated Dec. 11, 2008, for European Patent Application No. 96943576.7 (15 pages).
Opponent-Appellant's Grounds of appeal filed Apr. 21, 2009, for European Patent Application No. 96943576.7 (17 pages).
In Response to the Opponent-Appellant's Grounds of Appeal filed Sep. 25, 2009, for European Patent Application No. 96943576.7 (14 pages).
Official Communication dated Jan. 9, 2009, for European Patent Application No. 03018949.2 (6 pages).
Response to Official Communication and request for further processing filed Nov. 5, 2009, for European Patent Application No. 03018949.2 (3 pages).
Arakawa et al.,Arch. Biochem. Biophs., 308: 267-273 (1994).
Bargmann et al.,The Oncogene Handbook, pp. 107-119 (1988).
Berchuck et al.,Cancer Res., 50: 4087-4091 (1990).
Campos-Gonzalez et al.,Growth Factors, 4 (4): 305-316 (1991).
Curiel,Gene Therapy, 2: 20 (1995).
Coussens et al.,Science230: 1132-1139 (1985).
Deshane et al.,Gynecol. Oncol. 59: 8-14 (1995).
Deshane et al.,Journal of Investigative Medicine32: 328A (1995).
Drevin et al.,Oncogene2: 387-394 (1988).
Falls et al.,Cell72: 801-815 (1993).
Fendly et al.,Cancer Res., 50: 1550-1558 (1990).
Fukushige et al.,Mol. Cell Biol., 6: 955-958 (1986).
Grim et al.,Cancer Gene Therapy, 1: 333-334 (1994).
Harwerth et al.,Br. J. Cancer, 68: 1140-1145 (1993).
Harlow and Lane,Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988).
Holmes et al.,Science, 256: 1205-1210 (1992).
Hudziak et al.,Mol. Cell Biol., 9: 1165-1172 (1989).
Kallioniemi et al.,Int. J. Cancer, 49: 650-655 (1991).
Kelley et al.,Biochemistry, 31: 5434-5441 (1992).
Kerr et al.,Br. J. Cancer, 26: 239-257 (1972).
King et al.,Science, 229: 974-976 (1985).
Kita et al.,Biochemical and Biophysical Research Communications, 226: 59-69 (1996).
Korman et al.,Proc. Natl. Acad. Sci. USA, 84: 2150-2154 (1987).
Kraus et al.,Proc. Natl. Acad. Sci. USA, 86: 9193-9197 (1989).
Lin et al.,Gene, 44: 201-209 (1986).
Maniatis et al.,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory (1982).
Marchionni et al.,Nature, 362: 312-318 (1993).
Mendelsohn,Cancer Cells, 7: 359-362 (1989).
Muss et al.,N. Engl. J. Med, 330: 1260-1266 (1994).
Philo et al.,J. Biol. Chem., 269: 27840-27846 (1994).
Plowman et al.,Proc. Natl. Acad. Sci. USA, 90: 1746-1750 (1993).
Press et al., inEffects of Therapy on Biology and Kinetics of the Residual Tumor, Part A: Preclinical Aspects pp. 209-221 (1990).
Remington's Pharmaceutical Sciences, 18thed. A.R. Gennaro, ed. Mack, Easton, PA (1990).
Rilke et al.,Int. J. Cancer, 49: 44-49 (1991).
Ro et al.,Cancer Res., 49: 6941-6944 (1989).
Savill et al.,Nature, 343: 170-173 (1990).
Schechter et al.,Nature, 312: 515-516 (1984).
Seaver,Gen Eng. News., 14(4): 10 and 21 (1994).
Semba et al.,Proc. Natl. Acad. Sci. USA, 82: 6497-6501 (1985).
Slamon et al.,Science, 235: 177-182 (1987).
Slamon et al.,Science, 244: 707-712 (1989).
Srinivas et al.,Cancer Immunol. Immunother, 36: 397-402 (1993).
Stancovski et al.,Proc. Natl. Acad. Sci. USA, 88: 8691-8695 (1991).
Tagliabue et al.,Int. J. Cancer, 47: 933-937 (1991).
Takagi,J. Chromatogr., 506: 409-446 (1990).
Vitetta and Uhr,Cancer Res., 54: 5301-5309 (1994).
Wright et al.,Cancer Res., 49: 2087-2090 (1989).
Wu et al.,J. Clin. Invest., 95: 1897-1905 (1995).
Wyllie, A. ,Int. Rev. Cytol., 68: 251-306 (1980).
Wyllie et al.,Nature, 284: 555-556 (1980).
Xu et al.,Int. J. Cancer., 53: 401-408 (1993).
Yarden,Proc. Natl. Acad. Sci. USA, 87: 2569-2573 (1990).
Walker et al.,Brit. J. Cancer, 60: 426-429 (1989).
Wen et al.,Cell, 69: 559-572 (1992).
Hudziak, Robert M. et al., “Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells,”Proc. Natl. Acad. Sci. USA, 85:5102-5106 (1988).
European Search Report, for counterpart European Application No. 03 01 8949, dated Nov. 10, 2003.
Deshane et al., “Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cells lines,” Gene Therapy, 1: 332-337 (1994).
George et al., “Redirection of T cell-mediated cytotoxicity by a recombinant single-chain fv molecule,” Journal of Immunology, 152: 1802-1811 (1994).
Gruber et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed inEscherichia coli,” Journal of Immunology, 152: 5368-5374 (1994).
Harris et al., “The induction of apoptosis in human mammary luminal epithelial cells by expression of activated c-neuand its abrogation by glucocorticoids,” British Journal of Cancer, 72: 386-392 (1995).
Kyakumoto et al., “Co-expression of epidermal growth factor-receptor and c-erbB-2 proto-oncogene product in human salivary-gland adenocarcinoma cell line HSG and the implications for HSG cell autocrine growth,” Archives of Oral Biology, 39(7): 569-580 (1994).
Lippman et al., “The role of the erbB2 receptor and its ligands in human breast cancer,” Journal of Immunotherapy, 14(4): 369 (1993).
Freshney, Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer, Bio/Technology, 1994, 12: 320.
Drexler et al., Leukemia and Lymphoma, 1993, 9: 1-25.
Gura, Science, 1997, 278: 1041-1042.
Jain, Sci. Am., 1994, 271: 58-65.
Curti, Crit. Rev. in Oncology/Hematology, 1993, 14: 29-39.
Stancovski et al., PNAS, USA, 1991, 88: 8691-8695.
Lewis et al., Cancer Immunology Immunotherapy, 1993, 37: 255-263.
Strobel et al., Gynecologic Oncology, 1999, 73: 362-367.
Voskoglou-Nomikos et al., Clinical Cancer Research, 2003, 9: 4227-4239.
Cell Lines in the In Vitro Screen, p. 1-3, printed Apr. 10, 2006.
MDA-MB-435: Breast or Melanoma Origin?, printed Apr. 10, 2006.
Shepard et al., J of Clinical Immunology, 1991, 11: 117-127.
Le et al., Clinical Cancer Research, 2000, 6: 260-270.
Mohsin et al

Affiliated with

Also associated with

Rating

Antibody-induced apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody-induced apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody-induced apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4241138